Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avinger Inc (AVGR)

Avinger Inc (AVGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,132
  • Shares Outstanding, K 6,425
  • Annual Sales, $ 7,920 K
  • Annual Income, $ -27,560 K
  • 60-Month Beta 1.55
  • Price/Sales 0.74
  • Price/Cash Flow N/A
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.60
  • Growth Rate Est. (year over year) +17,939.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.77 +44.16%
on 10/10/19
1.16 -4.31%
on 09/19/19
-0.04 (-3.48%)
since 09/18/19
3-Month
0.77 +44.16%
on 10/10/19
2.47 -55.06%
on 07/26/19
-1.32 (-54.32%)
since 07/18/19
52-Week
0.77 +44.16%
on 10/10/19
12.60 -91.19%
on 04/10/19
-10.19 (-90.18%)
since 10/18/18

Most Recent Stories

More News
Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

SPSC : 47.18 (-2.82%)
SWKS : 87.77 (+0.25%)
VAR : 114.62 (+0.44%)
AVGR : 1.11 (+21.98%)
TUES : 1.32 (-4.01%)
Avinger Announces Full Commercial Launch of Pantheris SV

Product Shipped to 25 U.S. Accounts

AVGR : 1.11 (+21.98%)
Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24

REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that...

AVGR : 1.11 (+21.98%)
Avinger Announces Commercial Launch and First Patients Treated in Hong Kong

REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis...

AVGR : 1.11 (+21.98%)
Avinger Supports Peripheral Artery Disease (PAD) Awareness Month with Physician and Patient Programs in September

REDWOOD CITY, CA / ACCESSWIRE / September 4, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system...

AVGR : 1.11 (+21.98%)
Avinger Announces 50th Patient Treated in Pantheris SV Initial Launch

Preparing for Full Commercial Launch in September

AVGR : 1.11 (+21.98%)
Avinger Closes $4.5 Million Equity Offering

Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its...

AVGR : 1.11 (+21.98%)
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock

Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the...

AVGR : 1.11 (+21.98%)
Avinger Announces Proposed Underwritten Public Offering of Common Stock

Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten...

AVGR : 1.11 (+21.98%)
Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference

REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis...

AVGR : 1.11 (+21.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade AVGR with:

Business Summary

Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company's product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City,...

See More

Key Turning Points

2nd Resistance Point 1.34
1st Resistance Point 1.22
Last Price 1.11
1st Support Level 0.92
2nd Support Level 0.74

See More

52-Week High 12.60
Fibonacci 61.8% 8.08
Fibonacci 50% 6.69
Fibonacci 38.2% 5.29
Last Price 1.11
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar